| 标题： | 雾化吸入疗法合理用药专家共识（2024版） |
| title： | Expert Consensus on Rational Use of Drugs in Nebulized Inhalation Therapy (2024 Edition) |
| 版本： | 更新版 |
| version： | Updated |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 涉及雾化疗法应用的各科医务工作者，如呼吸科、急诊科、儿科、老年科等的医生、药师及护士等 |
| Guide users： | Healthcare professionals from various disciplines involved in the application of nebulized therapy, such as doctors, pharmacists and nurses in respiratory departments, emergency departments, pediatrics, geriatrics, etc. |
| 证据分级方法： | A级(高质量证据):直接相关的高质量指南提供的高质量研究、通过Cochrane系统评价的高质量研究、高质量随机对照试验或观察性研究得出的一致性结果，且要求证据体包含的研究数量及人群特征充足、样本量大，能提供精确的效应估计值。同时，没有发现其他局限性。 B级(中等质量证据):直接相关的高质量指南提供的研究、通过Cochrane系统评价的研究、随机对照试验或观察性研究中，存在部分可影响效应估计值的设计局限;或部分研究结果显示出不一致性:或虽然效应估计值显示有临床意义，但证据体包含的研究数量及人群特征不够充足、样本量有限。同时，没有发现其他局限性。C级(低质量证据):直接相关的高质量指南提供的研究、通过Cochrane系统评价的研究、随机对照试验或观察性研究中，绝大多数存在可影响效应估计值的严重设计局限;或各研究结果显示出明显的不一致性，或证据体包含的研究数量及人群特征很少，样本量小，效应估计值不精确，或证据存在间接性或其他严重的局限性。 专家意见:没有足够的研究证据支持，指南工作组根据临床经验和专业知识达成了共识，但未直接提供专家证据 |
| Evidence grading method： | Level A (high-quality evidence): consistent results obtained from high-quality studies provided by directly related high-quality guidelines, high-quality studies evaluated through the Cochrane system and high-quality randomized controlled trials or observational studies; And it is required that the evidence body contains sufficient research quantity and population characteristics, with a large sample size, and provide accurate effect estimates. At the same time, no other limitations were found. Level B (medium quality evidence): There are design limitations in studies provided by directly related high-quality guidelines, studies evaluated through the Cochrane system, randomized controlled trials or observational studies, that may affect the estimation of effects; Or some research results show inconsistency; Or although the estimated value of the effect shows clinical significance, the evidence body contains insufficient research quantity and population characteristics, and the sample size is limited. At the same time, no other limitations were found. Level C (low-quality evidence): In studies provided by directly related high-quality guidelines, studies evaluated through the Cochrane system, randomized controlled trials or observational studies, the vast majority have serious design limitations that can affect the estimated effects; Or the results of various studies show significant inconsistency; OR the number of studies and population characteristics included in the evidence body is small, the sample size is small, and the estimated effects are inaccurate; Or the evidence has indirectness or other serious limitations. Expert opinion: There is insufficient research evidence to support it. The guidelines working group reached a consensus based on clinical experience and professional knowledge but did not directly provide expert evidence. |
| 制定单位： | 中华医学会临床药学分会 |
| Formulating unit： | Chinese Society of Clinical Pharmacy |
| 注册时间： | 2024-02-01 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN234 |
| Registration number： | |
| 指南制订的目的： | 雾化吸入疗法是呼吸系统相关疾病的重要治疗手段之一。然而在我国由于医务人员对雾化吸入疗法及其药物认识不足，临床应用中存在许多不合理用药现象。虽然《雾化吸入疗法合理用药专家共识》（2019版）已经对诸多问题进行了解答与回应，但随着近年来雾化新药和装置陆续上市，以及呼吸系统疾病流行病学发生变化，雾化吸入疗法的应用又出现了新的问题。此次共识更新将结合流行病学变化，纳入最新的循证依据、药物与装置等信息，为规范雾化吸入疗法的合理应用提供最新的依据。 |
| Purpose of the guideline： | Nebulized inhalation therapy is one of the important treatments for respiratory diseases. However, in China, due to insufficient understanding of nebulized inhalation therapy and drugs, there are many irrational use phenomena in clinical applications. Although the "Expert Consensus on the Rational Use of Drugs in Nebulized Inhalation Therapy" (2019 Edition) has answered and responded to many questions, with the launch of new drugs and devices in recent years, as well as changes in the epidemiology of respiratory diseases, new problems have arisen with the application of nebulized inhalation therapy. This consensus update will combine epidemiological changes and incorporate the latest evidence-based evidence, drugs and devices, etc., to provide the latest basis for standardizing the rational application of nebulized inhalation therapy. |
